Please login to the form below

Not currently logged in
Email:
Password:

accelerated review

This page shows the latest accelerated review news and features for those working in and with pharma, biotech and healthcare.

AZ’s Farxiga cuts risk of death in chronic kidney disease

AZ’s Farxiga cuts risk of death in chronic kidney disease

This accelerated review was based on exploratory results from the EMPA-REG OUTCOME trial, which found that treatment with Jardiance reduced the risk of new-onset and worsening kidney disease by

Latest news

More from news
Approximately 1 fully matching, plus 63 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    In March 2017, AZ’s targeted lung cancer drug Tagrisso was one of the first medicines to gain approval through the Chinese Food and Drug Administration (CFDA)’s Priority Review pathway, ... Roxadustat is under accelerated review and, if approved,

  • Uncertainty, austerity and Brexit Uncertainty, austerity and Brexit

    Alongside this, rumours that NHS England was planning to include biosimilars on the Accelerated Access Pathway, the flagship policy intervention designed to speed up the use of innovative products, would amount ... Sciences Industrial Strategy and the

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    Specifically, this should include building on the recommendations put forward in the Life Science Industrial Strategy and the Accelerated Access Review, to streamline access evaluation processes for new therapies and enable

  • Macron, Merkel and May: implications of the 2017 elections for the life science industry Macron, Merkel and May: implications of the 2017 elections for the life science industry

    Furthermore, the 2017 Conservative Party election manifesto promised to ‘implement the findings of the Accelerated Access Review to make sure that patients get new drugs and treatments faster while the NHS

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Expedited drug development and nonstandard review approval pathways are the new norm in the US, but in the EU special approval procedures are not as common. ... In 2016 special approval pathways and designations like Fast Track, Breakthrough, Accelerated

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...

Latest intelligence

Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...
Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...

Infographics